Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Conditions:   NSCLC Stage IV;   KRAS Gene Mutation;   PD-1 Antibody;   Chemotherapy Effect Interventions:   Drug: SHR-1210;   Drug: Apatinib;   Drug: Pemetrexed;   Drug: Carboplatin Sponsors:   Jiangsu HengRui Medicine Co., Ltd.;   Shanghai Chest Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials